Implantation of XXXX -eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels.

@entity1 @entity66 @entity3446 @entity177 @entity3979
AIMS: The clinical effectiveness of @entity3446 -eluting stents (SES) for treatment of @entity1 with saphenous vein graft disease is not well defined. This analysis sought to evaluate the clinical follow-up after treatment of stenotic saphenous vein grafts using SES in a large @entity1 registry. @entity1 treated with SES for saphenous vein graft disease were compared with @entity1 receiving SES in native @entity66 . METHOD: This is a subanalysis from the prospective multicenter German Cypher Stent Registry. Only @entity1 with completed 6 months clinical follow-up were included. The analysis comprises 344 @entity1 with 353 lesions in saphenous vein grafts treated with 400 SES (Cypher, Cordis Inc., Cordis Corp., Warren, New Jersey, USA) and 6411 @entity1 with 7607 native coronary artery lesions treated with 8725 SES. RESULTS: Mean SES length per lesion was 22.6+/-11.7 mm and mean stent diameter 3.0+/-0.3 mm in saphenous vein graft lesions. Target vessel revascularization rate was 18.1% and major adverse cardiovascular events (MACE) rate was 23.8% at 6-month follow-up after SES implantation for saphenous vein graft lesions. Even after adjustment for different baseline characteristics, @entity177 and MACE rate were significantly higher after SES implantation for saphenous vein graft lesions than for native @entity3979 [odds ratio: 2.10 (95% confidence interval: 1.40-3.13), P<0.001] and [odds ratio: 2.15 (95% confidence interval: 1.49-3.09), P<0.001], respectively. CONCLUSION: Treatment of saphenous vein graft disease is associated with high target vessel revascularization and MACE rates also with the use of SES if applied to unselected @entity1 . Target vessel revascularization and MACE rates remain significantly higher after SES for saphenous vein graft lesions than after SES in native @entity66 .
